Bionaut Pharmaceuticals and AnalytiCon Discovery Collaborate for Optimization of Novel Class of Anti-Cancer Compounds

21-Apr-2005

Bionaut Pharmaceuticals, Inc. and AnalytiCon Discovery GmbH announced a service and collaboration agreement to identify novel anti-cancer compounds that inhibit the ability of tumor cells to survive stress conditions. Bionaut will provide to the collaboration a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel® Pathway Reporter System to validate new compounds. AnalytiCon will apply its natural product and medicinal chemistry expertise to optimize the activity and selectivity of these compounds for further pre-clinical development by Bionaut. Financial terms were not disclosed.

"We are delighted to have the chemistry team at AnalytiCon developing novel analogues for our lead program in cancer," said Thomas Klein, Chief Operating Officer of Bionaut. "We believe their unique combination of expertise in natural products and analog medicinal chemistry will provide the fastest route to identify novel drug candidates to take forward towards human clinical studies."

"The novel biological screening capabilities of Bionaut, combined with our exceptional integrated natural productrelated expertise, make this a unique partnership," said Lutz Müller-Kuhrt, Ph.D., CEO of AnalytiCon Discovery. "Bionaut's whole cell assays, which were used to identify this class of compounds that target tumor cells' response to stress, can also be used to rapidly validate the selectivity and efficacy of the compound analogues we develop for Bionaut."

https://www.bionity.com/en/news/45323/bionaut-pharmaceuticals-and-analyticon-discovery-collaborate-for-optimization-of-novel-class-of-anti-cancer-compounds.html